Chemours Company (The)
CC
Positions held
Your positionsCC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Chemours operates in the specialty chemicals industry, which is essential for various sectors including automotive, electronics, and construction, providing a stable demand base.
- Revenue increased by 15% compared to the prior quarter, reaching $1.6 billion.
- Gross margin improved to 18% from 15.4% in the previous quarter.
- The company's operating margin has been negative, indicating ongoing profitability challenges.
- Net income for the most recent quarter was -$274 million, reflecting significant losses.
- The overall score indicates a 'Sell' signal with a score of -6.00, suggesting negative market sentiment.
Fundamentals
| Market cap | $2.08B | Enterprise value | $5.53B | Trailing P/E | — | Forward P/E | 7.17 |
| PEG | 1.60 | Price / book | -42.42 | Beta | 1.40 | Dividend yield | 2.53% |
| Revenue growth | -1.5% | Earnings growth | — | Gross margin | 15.4% | Operating margin | 1.1% |
| Profit margin | -5.2% | ROE | -3.2% | ROA | 1.4% | Debt / equity | — |
| Current ratio | 1.66 | Free cash flow | $303.12M | Analyst recommendation | buy | Mean target | $18.33 |
| 52w high | $28.67 | 52w low | $10.44 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.4B | $1.3B | $1.5B | $1.6B | — |
| Op margin | -13.2% | 2.8% | -0.4% | 6.2% | -10.8% | — |
| Net income | -$274M | -$29.0M | -$61.0M | $60.0M | -$380M | — |
| Gross margin | 18.0% | 15.4% | 11.7% | 15.6% | 17.2% | — |
| Gross profit | $286M | $212M | $156M | $233M | $278M | — |
| Operating income | -$210M | $39.0M | -$5.0M | $93.0M | -$174M | — |
- Revenue +15% vs prior quarter ($1.6B vs $1.4B).
- Gross margin 18% (was 15.4% prior quarter).
- Operating margin compressed to -13.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $5.8B | $5.8B | $6.1B | $6.8B |
| Op margin | -0.5% | 7.3% | -2.0% | 11.5% |
| Net income | -$386M | $69.0M | -$253M | $578M |
| Gross margin | 15.5% | 19.8% | 21.4% | 23.7% |
| Gross profit | $902M | $1.1B | $1.3B | $1.6B |
| Operating income | -$28.0M | $421M | -$123M | $786M |
Headlines — watch
• [WARN · legal] Chemours Shares Rise 6% After $455 Million North Carolina PFAS Settlement
• [WARN · legal] Chemours, DuPont and Corteva to Pay $455 Million in North Carolina PFAS Settlement
• [WARN · legal] Chemours, DuPont, Corteva Reach $455 Million PFAS Settlement With North Carolina
• [WARN · legal] Chemours, DuPont, Corteva reach $455 PFAS settlement with North Carolina
News
2026-10-05 · UBS Adjusts Chemours Price Target to $16 From $18, Maintains Neutral Rating
2026-09-29 · The Dividend Screener Says High Yield. But These Chemical Stocks Tell a Different Story
2026-09-29 · Are Options Traders Betting on a Big Move in Chemours Stock?
2026-09-29 · Lindt shares tumble 7% as chocolate maker cuts sales growth forecast
2026-09-17 · Did Chemours' (CC) US$455 Million PFAS Deal Just Reframe Its Long‑Term Liability Narrative?
2026-09-16 · Chemours (CC) Trims Losses While Core Demand Keeps Slipping
2026-09-11 · Chemours, DuPont, Corteva settle North Carolina PFAS claims for $455M
2026-09-11 · Chemours, DuPont, Corteva reach $455 PFAS settlement with North Carolina
2026-09-10 · Chemours Shares Rise 6% After $455 Million North Carolina PFAS Settlement
2026-09-10 · Chemours, DuPont and Corteva to Pay $455 Million in North Carolina PFAS Settlement
2026-09-10 · Chemours, DuPont, Corteva Reach $455 Million PFAS Settlement With North Carolina
2026-09-10 · DuPont, Chemours and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
Price (daily)
Full chart · RSI · MACD · patterns